Marimed (MRMD) reported $160M in revenue for fiscal 2025, +1.3% year on year. That ranks #2759 by revenue among 2853 SEC filers and #303 in Healthcare. It posted a net loss of −$14.5M for the same year. Revenue has grown 66.6% a year on average since 2011 ($125,607 then). The fiscal 2025 balance sheet shows $203M in total assets, $8.9M in cash and $76.0M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $160M | +1.3% | FY20252025-12-31 |
| Gross profitGrossProfit | $57.9M | −7.6% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$2.8M | −$5.4M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$14.5M | −$2.0M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $7.7M | +13.4% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $1.2M | −90.2% | FY20252025-12-31 |
| Total assetsAssets | $203M | −2.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest | $50.0M | −14.6% | FY20252025-12-31 |
| CashCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | $8.9M | +22.0% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $76.0M | −2.7% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $39.5M | −$3.8M | Open → |
| Q2 20262026-06-30 | $41.9M | −$3.6M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Marimed Inc.
- Ticker
- MRMD
- Exchange
- OTC
- SIC classification
- Medicinal Chemicals & Botanical Products (2833)
- Fiscal year end
- 12-31
- CIK
- 0001522767
Filings
- 10-QAug 13, 2026Open filing →
- 10-QMay 14, 2026Open filing →
- 10-KMar 12, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Syndax PharmaceuticalsSNDX | $172M | −$285M |
| RegenxbioRGNX | $170M | −$194M |
| Ginkgo BioworksDNA | $170M | −$313,000 |
| MarimedMRMD | $160M | −$14.5M |
| LiquidiaLQDA | $158M | −$68.9M |
| Heron TherapeuticsHRTX | $155M | −$20.0M |
| Airsculpt TechnologiesAIRS | $152M | −$11.7M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Marimed — Key figures |url=https://companiesranked.com/en/company/marimed |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Marimed — Key figures. CompaniesRanked. https://companiesranked.com/en/company/marimedBibTeX
@misc{companiesranked-en-company-marimed-2026,
author = {{CompaniesRanked}},
title = {{Marimed — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/marimed}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001522767-26-000030 · March 12, 2026
{{cite web |title=Marimed — Key figures — 10-K (0001522767-26-000030) |url=https://www.sec.gov/Archives/edgar/data/1522767/000152276726000030/mrmd-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-12}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.